Zhao et al. showed that disitamab vedotin (RC48) exerts antitumor effects in lung cancer cells by targeting both the HER2/PI3K/AKT and FOXA1/HER2/PI3K/AKT axes, with higher FOXA1 and HER2 correlating with worse prognosis [88]. This evidence concerns the gene PIK3CA and lung carcinoma.